The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis‐generating study
Abstract Background Inhibition of CDK7, a potent transcription regulator, may bring new hope for treating pancreatic ductal adenocarcinoma (PDAC), which is featured by large genetic heterogeneity and abundant KRAS mutations. This investigation aimed at exploring the discrepant efficacies of THZ1, a...
| Հիմնական հեղինակներ: | , , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Wiley
2023-12-01
|
| Շարք: | Clinical and Translational Medicine |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://doi.org/10.1002/ctm2.1500 |